Epigenetic Market Research
Epigenetics is a rapidly growing field with promising implications for treatment of cancer and other potential diseases. In recent times, research interest in epigenetics has burgeoned.
Epigenetic drugs are the chemical compounds or biologics causing epigenetic changes resulting in modified molecular protein expressions. These drugs, like Vidaza, Zolinza, Dacogen and Istodax, have the potential to trigger or suppress a protein expression process.
Research reveals that the global epigenetics market is forecasted to reach $18.2 billion by 2015.
The Epigenetic market research report provides insight into the pipeline status of epigenetic therapeutics by company and by stage, as well as a summary of the latest news and developments in this area. In addition to new developments and disease specific pipeline projects, the listed reports also contain extensive information in tabular format on a company’s full product pipeline, and products by phase of development with regard to the therapy area. The study also helps in keeping track of the industry-specific competitors and partners by better understanding their product pipeline.
The study basically aims at providing a comprehensive overview of the on-goings of the epigenetic drug therapy market.